Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: Business Wire
- Improvement observed in pancreatic function, as measured by C-peptide response, following 24 weeks of treatment with AMX0035; worsening is typically expected with disease progression based on natural history studies of Wolfram syndrome- Longer-term data for all participants who have completed Week 36 and Week 48 assessments showed sustained improvement over time- Improvements or stabilization observed across all secondary endpoints, including measures of glycemic control, vision, and patient- and clinician-reported impressions of overall disease burden- AMX0035 was generally well-tolerated in all participants- Amylyx plans to meet with the FDA and other stakeholders to inform a Phase 3 program and expects to provide an update in 2025- Topline data to be presented during a live webcast today at 1:30 p.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced positive topline data from the Phase 2 open-label HEL
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $10.00 price target on the stock, up previously from $4.20.MarketBeat
- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was given a new $4.00 price target on by analysts at Leerink Partners. They now have a "market perform" rating on the stock.MarketBeat
- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- Why Amylyx Pharmaceuticals Stock Was So Healthy This Week [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals reports results from pancreatic disease treatment trial [Seeking Alpha]Seeking Alpha
AMLX
Earnings
- 8/8/24 - Miss
AMLX
Analyst Actions
- 10/18/24 - HC Wainwright
AMLX
Sec Filings
- 10/25/24 - Form SC
- 10/17/24 - Form 8-K
- 10/2/24 - Form 4
- AMLX's page on the SEC website